[144] Supernus Pharmaceuticals, Inc. SEC Filing
Supernus Pharmaceuticals (SUPN) filed a Form 144 reporting a proposed sale of 1,412 shares of its common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $61,167.84 and the company reports 56,073,088 shares outstanding. The filing lists the acquisition of these shares as an in-kind distribution from NEA Partners on 11/16/2023, with the acquisition and payment dated 11/16/2023.
The filer indicates no securities sold in the past three months and includes standard representations about absence of undisclosed material adverse information. The notice appears to be a routine disclosure of an intended sale under Rule 144.
Supernus Pharmaceuticals (SUPN) ha depositato un Form 144 per la proposta vendita di 1.412 azioni ordinarie. Le azioni saranno vendute tramite Morgan Stanley Smith Barney LLC sul NASDAQ per un valore complessivo di $61.167,84; la societ脿 dichiara 56.073.088 azioni in circolazione. Il documento segnala che le azioni sono state acquisite come distribuzione in natura da NEA Partners il 16/11/2023, con acquisizione e pagamento nella stessa data.
Il dichiarante indica di non aver venduto titoli negli ultimi tre mesi e include le consuete dichiarazioni sull'assenza di informazioni negative rilevanti non divulgate. L'avviso sembra una comunicazione di routine relativa a una vendita prevista ai sensi della Rule 144.
Supernus Pharmaceuticals (SUPN) present贸 un Form 144 notificando la propuesta de venta de 1.412 acciones ordinarias. Las acciones se vender谩n a trav茅s de Morgan Stanley Smith Barney LLC en el NASDAQ por un valor agregado de $61,167.84 y la compa帽铆a reporta 56,073,088 acciones en circulaci贸n. La presentaci贸n indica que estas acciones se adquirieron como una distribuci贸n en especie de NEA Partners el 16/11/2023, con adquisici贸n y pago en esa misma fecha.
El declarante se帽ala que no ha vendido valores en los 煤ltimos tres meses e incluye las representaciones habituales sobre la ausencia de informaci贸n adversa material no divulgada. La notificaci贸n parece ser una divulgaci贸n rutinaria de una venta prevista bajo la Regla 144.
Supernus Pharmaceuticals(SUPN)電� 氤错喌欤� 1,412欤� 毵り皝 鞓堨爼鞛勳潉 氤搓碃頃橂姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 齑濎暋 $61,167.84鞐� 毵り皝霅� 鞓堨爼鞚措┌, 須岇偓電� 鞙犿喌 欤检嫕 靾橂ゼ 56,073,088欤茧 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 鞚� 欤检嫕霌れ澊 2023雲� 11鞗� 16鞚� NEA Partners搿滊秬韯� 順勲 攵勲鞍搿� 旆摑霅橃棃鞙茧┌ 旆摑 氚� 雽�旮� 歆�旮夒弰 臧欖潃 雮犾鞐� 鞚措（鞏挫雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟.
鞁犼碃鞛愲姅 歆�雮� 3臧滌洈臧� 毵る弰頃� 歃濌秾鞚� 鞐嗠嫟瓿� 氚濏瀳瓿� 鞛堨溂氅�, 牍勱车臧滊悳 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗠嫟電� 韱奠儊鞝侅澑 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟. 鞚� 瓿奠電� Rule 144鞐� 霐半ジ 鞓堨爼 毵り皝鞚� 鞚检儊鞝侅澑 瓿奠嫓搿� 氤挫瀰雼堧嫟.
Supernus Pharmaceuticals (SUPN) a d茅pos茅 un Form 144 signalant la proposition de vente de 1 412 actions ordinaires. Les actions doivent 锚tre vendues par l'interm茅diaire de Morgan Stanley Smith Barney LLC sur le NASDAQ pour une valeur totale de 61 167,84 $ et la soci茅t茅 d茅clare 56 073 088 actions en circulation. Le d茅p么t indique que ces actions ont 茅t茅 acquises en tant que distribution en nature de NEA Partners le 16/11/2023, avec acquisition et paiement 脿 la m锚me date.
Le d茅clarant indique n'avoir vendu aucun titre au cours des trois derniers mois et inclut les d茅clarations habituelles quant 脿 l'absence d'informations d茅favorables significatives non divulgu茅es. L'avis semble 锚tre une divulgation routini猫re d'une vente pr茅vue en vertu de la Rule 144.
Supernus Pharmaceuticals (SUPN) reichte ein Formular 144 ein, in dem der geplante Verkauf von 1.412 Stammaktien gemeldet wird. Die Aktien sollen 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ verkauft werden, mit einem Gesamtmarktwert von $61.167,84; das Unternehmen gibt 56.073.088 ausstehende Aktien an. Die Einreichung vermerkt, dass diese Aktien am 16.11.2023 als Sachverteilung von NEA Partners erworben wurden, wobei Erwerb und Zahlung am selben Datum erfolgten.
Der Einreicher gibt an, in den vergangenen drei Monaten keine Wertpapiere verkauft zu haben, und enth盲lt die 眉blichen Zusicherungen 眉ber das Fehlen nicht offengelegter wesentlicher negativer Informationen. Die Mitteilung erscheint als routinem盲脽ige Bekanntgabe eines geplanten Verkaufs nach Rule 144.
- Complete Rule 144 disclosure including broker, acquisition details, aggregate market value and outstanding shares
- Brokered sale through a regulated firm (Morgan Stanley Smith Barney LLC) listed
- Filer attests to absence of undisclosed material adverse information and reports no sales in past three months
- None.
Insights
TL;DR: Small insider sale disclosed: 1,412 shares worth $61,167.84, routine compliance filing under Rule 144.
The Form 144 provides required details for a proposed sale of 1,412 common shares via Morgan Stanley Smith Barney on NASDAQ. The shares were acquired in-kind from NEA Partners on 11/16/2023. With 56,073,088 shares outstanding reported, the transaction size is limited in absolute terms and the filing contains the customary representation that no undisclosed material adverse information is known.
TL;DR: Filing meets Rule 144 disclosure elements; no past three-month sales reported.
The notice includes broker details, acquisition date and nature, aggregate market value, and outstanding share count, aligning with Rule 144 form requirements. It also contains the signature representation regarding material information and a statement about reliance on any 10b5-1 plan if applicable. No recent sales are reported, suggesting this is a standalone planned disposition.
Supernus Pharmaceuticals (SUPN) ha depositato un Form 144 per la proposta vendita di 1.412 azioni ordinarie. Le azioni saranno vendute tramite Morgan Stanley Smith Barney LLC sul NASDAQ per un valore complessivo di $61.167,84; la societ脿 dichiara 56.073.088 azioni in circolazione. Il documento segnala che le azioni sono state acquisite come distribuzione in natura da NEA Partners il 16/11/2023, con acquisizione e pagamento nella stessa data.
Il dichiarante indica di non aver venduto titoli negli ultimi tre mesi e include le consuete dichiarazioni sull'assenza di informazioni negative rilevanti non divulgate. L'avviso sembra una comunicazione di routine relativa a una vendita prevista ai sensi della Rule 144.
Supernus Pharmaceuticals (SUPN) present贸 un Form 144 notificando la propuesta de venta de 1.412 acciones ordinarias. Las acciones se vender谩n a trav茅s de Morgan Stanley Smith Barney LLC en el NASDAQ por un valor agregado de $61,167.84 y la compa帽铆a reporta 56,073,088 acciones en circulaci贸n. La presentaci贸n indica que estas acciones se adquirieron como una distribuci贸n en especie de NEA Partners el 16/11/2023, con adquisici贸n y pago en esa misma fecha.
El declarante se帽ala que no ha vendido valores en los 煤ltimos tres meses e incluye las representaciones habituales sobre la ausencia de informaci贸n adversa material no divulgada. La notificaci贸n parece ser una divulgaci贸n rutinaria de una venta prevista bajo la Regla 144.
Supernus Pharmaceuticals(SUPN)電� 氤错喌欤� 1,412欤� 毵り皝 鞓堨爼鞛勳潉 氤搓碃頃橂姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 齑濎暋 $61,167.84鞐� 毵り皝霅� 鞓堨爼鞚措┌, 須岇偓電� 鞙犿喌 欤检嫕 靾橂ゼ 56,073,088欤茧 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 鞚� 欤检嫕霌れ澊 2023雲� 11鞗� 16鞚� NEA Partners搿滊秬韯� 順勲 攵勲鞍搿� 旆摑霅橃棃鞙茧┌ 旆摑 氚� 雽�旮� 歆�旮夒弰 臧欖潃 雮犾鞐� 鞚措（鞏挫雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟.
鞁犼碃鞛愲姅 歆�雮� 3臧滌洈臧� 毵る弰頃� 歃濌秾鞚� 鞐嗠嫟瓿� 氚濏瀳瓿� 鞛堨溂氅�, 牍勱车臧滊悳 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗠嫟電� 韱奠儊鞝侅澑 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟. 鞚� 瓿奠電� Rule 144鞐� 霐半ジ 鞓堨爼 毵り皝鞚� 鞚检儊鞝侅澑 瓿奠嫓搿� 氤挫瀰雼堧嫟.
Supernus Pharmaceuticals (SUPN) a d茅pos茅 un Form 144 signalant la proposition de vente de 1 412 actions ordinaires. Les actions doivent 锚tre vendues par l'interm茅diaire de Morgan Stanley Smith Barney LLC sur le NASDAQ pour une valeur totale de 61 167,84 $ et la soci茅t茅 d茅clare 56 073 088 actions en circulation. Le d茅p么t indique que ces actions ont 茅t茅 acquises en tant que distribution en nature de NEA Partners le 16/11/2023, avec acquisition et paiement 脿 la m锚me date.
Le d茅clarant indique n'avoir vendu aucun titre au cours des trois derniers mois et inclut les d茅clarations habituelles quant 脿 l'absence d'informations d茅favorables significatives non divulgu茅es. L'avis semble 锚tre une divulgation routini猫re d'une vente pr茅vue en vertu de la Rule 144.
Supernus Pharmaceuticals (SUPN) reichte ein Formular 144 ein, in dem der geplante Verkauf von 1.412 Stammaktien gemeldet wird. Die Aktien sollen 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ verkauft werden, mit einem Gesamtmarktwert von $61.167,84; das Unternehmen gibt 56.073.088 ausstehende Aktien an. Die Einreichung vermerkt, dass diese Aktien am 16.11.2023 als Sachverteilung von NEA Partners erworben wurden, wobei Erwerb und Zahlung am selben Datum erfolgten.
Der Einreicher gibt an, in den vergangenen drei Monaten keine Wertpapiere verkauft zu haben, und enth盲lt die 眉blichen Zusicherungen 眉ber das Fehlen nicht offengelegter wesentlicher negativer Informationen. Die Mitteilung erscheint als routinem盲脽ige Bekanntgabe eines geplanten Verkaufs nach Rule 144.
FAQ
What does Supernus (SUPN) report in this Form 144?
When were the shares being sold acquired?
How many Supernus shares are outstanding according to the filing?
Does the filing report any securities sold in the past three months?
Who is the broker handling the proposed sale?
